ArticleJournal of experimental & clinical cancer research : CR2022

TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1α degradation.

Yongchang Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.